Why did the FDA update HRT warnings

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

The FDA updated HRT warnings because new, more reliable long-term research showed that certain risks were different than previously believed. The FDA wanted women and clinicians to have clearer, more accurate information so treatment decisions could be truly informed and individualized.

Why the FDA updated the warnings

According to FDA.gov, the FDA revised its Hormone Replacement Therapy labels after large studies — especially the Women's Health Initiative (WHI) — provided updated data on how estrogen and progesterone affect the body over many years. According to the WHI, these studies clarified which risks are real, which are small, and which relate only to certain women. The goal was to ensure transparent information about blood clots, stroke, cardiovascular risk, breast cancer, and how these risks shift with age, dose, and type of hormone. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What changed and why it matters

• More precise understanding of risk: Earlier beliefs were based on smaller studies. According to the WHI, newer, much larger studies showed that risks are not one-size-fits-all. For example, cardiovascular risk was found to rise mainly in women who started HRT long after menopause, not in women who started early.
• Differences between estrogen alone vs. estrogen plus progesterone: According to FDA Drug Safety Communications, data showed that adding progesterone (needed for women with a uterus) may slightly increase breast cancer risk over many years, while estrogen alone did not show this same pattern.
• Age and timing matter: According to FDA.gov, the FDA wanted labels to reflect that the body responds differently before age 60 or within 10 years of menopause compared with later years.
• Route of delivery matters: According to NAMS, studies clarified that transdermal estrogen (patch, gel, spray) may carry a lower clot risk than oral pills. Labels were updated to acknowledge these distinctions.
• Encouraging individualized dosing: According to the FDA-approved prescribing information for commercially available HRT products, the revised warnings highlight using the lowest effective dose for each woman's needs — not because hormones are inherently problematic, but because the lowest effective dose is sound medical practice.

What the update does NOT mean

According to ACOG, the FDA update does not mean HRT is unsafe for most women — it means we understand it better. For many healthy women in early menopause, commercially available HRT may remain an option for symptom relief and long-term bone support. The warnings simply ensure that every woman receives honest, current information so she may make a choice in consultation with a qualified prescriber that reflects her individual health profile and comfort level.